DARA BioSciences Announces Completion of Toxicology Studies for ... - MarketWatch

DARA BioSciences Announces Completion of Toxicology Studies for ...
MarketWatch - 1 hour ago
DB959 is a novel insulin sensitizer designed to correct the insulin resistance of Type 2 diabetes. In pre-clinical studies, the drug has demonstrated potent ...